Drug Profile
Research programme: long-acting protein therapeutics - OPKO Health
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator PROLOR Biotech
- Developer OPKO Health
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Atherosclerosis; Rheumatoid arthritis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Atherosclerosis in USA
- 16 Jul 2016 No recent reports of development identified for research development in Rheumatoid-arthritis in USA
- 29 Aug 2013 PROLOR Biotech has been acquired by OPKO Health